Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JLP-1401 vs Co-administration of Rosuvastatin and Telmisartan/Amlodipine
NCT03247140Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + rosuvastatin in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jun 2017; status: completed.
02
Drugs
telmisartan + amlodipine + rosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03247140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247140.